User profiles for Lisa A. Carey
LISA A. CAREY MD, ScM, FASCOUniversity of North Carolina Lineberger Comprehensive Cancer Center Verified email at med.unc.edu Cited by 57944 |
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
ContextGene expression analysis has identified several breast cancer subtypes, including
basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (…
basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (…
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
Purpose: Gene expression analysis identifies several breast cancer subtypes. We examined
the relationship of neoadjuvant chemotherapy response to outcome among these breast …
the relationship of neoadjuvant chemotherapy response to outcome among these breast …
[HTML][HTML] The molecular portraits of breast tumors are conserved across microarray platforms
Background Validation of a novel gene expression signature in independent data sets is a
critical step in the development of a clinically useful test for cancer patient risk-stratification. …
critical step in the development of a clinically useful test for cancer patient risk-stratification. …
Molecular classification and molecular forecasting of breast cancer: ready for clinical application?
Profiling breast cancer with expression arrays has become common, and it has been suggested
that the results from early studies will lead to understanding of the molecular differences …
that the results from early studies will lead to understanding of the molecular differences …
[HTML][HTML] Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Background Patients with human epidermal growth factor receptor 2 (HER2)–positive
metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted …
metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted …
[HTML][HTML] Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline
LA Korde, MR Somerfield, LA Carey… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature
on neoadjuvant therapy for breast cancer and provide recommended care options. …
on neoadjuvant therapy for breast cancer and provide recommended care options. …
[HTML][HTML] Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and …
…, JR Bellon, D Collyar, OM Hahn, LA Carey… - Journal of clinical …, 2015 - ncbi.nlm.nih.gov
Purpose One third of patients with triple-negative breast cancer (TNBC) achieve pathologic
complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 (…
complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 (…
Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update.
…, MEH Hammond, M Dowsett, SE McKernin, LA Carey… - 2020 - repository.icr.ac.uk
Purpose: To update key recommendations of the American Society of Clinical Oncology/College
of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in …
of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in …
Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer
Of the estimated 1 million cases of breast cancer diagnosed annually worldwide, it is estimated
that over 170,000 will harbor the triple-negative (estrogen receptor/progesterone receptor…
that over 170,000 will harbor the triple-negative (estrogen receptor/progesterone receptor…
[HTML][HTML] Sacituzumab govitecan in metastatic triple-negative breast cancer
Background Patients with metastatic triple-negative breast cancer have a poor prognosis.
Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the …
Sacituzumab govitecan is an antibody–drug conjugate composed of an antibody targeting the …